The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
Reference
Equistro has introduced Legaphyton to its range of supplements. Legaphyton has been developed to support liver function. It incorporates a new and patented complex called Siliphos®.
Siliphos® is a complex of concentrated Milk Thistle fruit extract and phospholipids, and is a source of readily available carbohydrates important for liver support.
Milk Thistle (silymarin) extract has documented virtues in liver support and is rich in flavanoligan (Silybin), while phospholipids (phosphatidylcholine) maintain healthy liver cell membrane function and repair and are crucial for essential lipoprotein transport in the liver.
“The liver is one of the most important organs and performs more often than one realises,” said Val Day, Equistro’s product manager. “Legaphyton has been introduced to give an extra boost to the horse’s liver function and help the liver fulfil its varied role.”
Equistro Legaphyton is available in 900g packs, which is sufficient for 30 days for a standard 500kg horse. Ask your Vetoquinol representative for more details or visit http://www.vetoquinol.co.uk/
.
The current inventory of Equip Artervac has an expiry date of March 29, 2023 and the company is not expecting a new batch to be available until the end of September 2023.
Zoetis says it has been working with relevant organisations to implement a plan to mitigate the impact on breeders.
The Thoroughbred Breeders Association has published advice for a blood sampling scheme at: https://www.rossdales.com/news-events/tba-members-equine-vaccine-advice-regarding-disruption-to-supply-of-equip-artervac, but Zoetis highlights that the advice requires action two weeks after the most recent EVA vaccination.
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0345 300 8034
Currently fewer than one in ten veterinary students opt to go into equine practice. BEVA says it hopes that the new scheme will provide a broader base of students with an insight into the world of equine veterinary medicine and open more eyes to what’s great about being an equine vet.
Katie Roberts the President of the Association of Veterinary Students said: "This is a very exciting opportunity for students. Anecdotally, we know that some students can feel very daunted by equine practice, especially if they don’t come from a traditionally horsey background. Being able to become involved with BEVA at no cost means that they can get a true taste of the equine veterinary world in addition to their experiences on EMS, and I’m sure this will pique the interest of our members."
As part of their free membership, students will also have access to:
The initiative has been made possible with sponsorship from Baker McVeigh, CVS Group, IVC, Newmarket Equine Hospital, Rossdales, VetPartners, and XLVets.
For further information about student membership of BEVA visit: https://www.beva.org.uk/Join-BEVA/vet-student
Dechra Veterinary Products has launched Osphos, an intramuscular clodronic acid injection for the control of clinical signs associated with the bone resorptive processes of navicular syndrome in horses, the only such licensed product in the UK.
Dechra says it expects Osphos to change the way chronic lameness caused by navicular syndrome is tackled by equine vets.
According to the company, clinical trials of Osphos showed 74.7% of horses experienced improvement by at least one lameness grade at 56 days post treatment.
Dechra brand manager Emma Jennings said: "Osphos intramuscular injection contains the bisphosphonate clodronic acid which inhibits resorption in the navicular bone by binding to hydroxyapatite crystals and by direct cellular effects on osteoclasts.
"We are delighted with the results of the trials, which proved that Osphos is effective at 6 months post-treatment. We're looking forward to being able to support equine vets, vet nurses and practices by providing an intramuscular Clodronic acid injection for horses."
Dechra also says studies showed that mild transient colic was seen following just 1.6 per cent of treatments.
Osphos 60 mg/ml solution for injection for horses is available from September 2014.
WebLeC has launched a monthly online equine CPD service.
One hour live interactive sessions will take place every third Thursday at 7:30 pm. A single meeting costs £30 plus VAT, or savings can be made by taking out a flexible subscription that allows the user to choose any 12 meetings for the cost of 10 over a period of up to 24 months.
The next meeting is on 22nd September and is entitled: Colic Decision making: When to wake up the surgeon and what pain control to use. The presenter is Debra Archer form the University of Liverpool. Further details and registration links can be found at: http://www.ledstonequine.co.uk/weblec_lectures/colic.html
In addition, a recording of WebLeC's 6th meeting, which was held in partnership with BEVA and the VDS and dealt with the new guidelines and forms for pre-purchase examinations of horses, is now available to view free online at: www.bitly.com/weblecbevaPPE. Use the password: b3va to get access, and you will receive a CPD certificate if you fill in the registration form.
WebLeC has also been asked to host BEVA's online CPD and will be announcing further details of their meetings soon.
Rather than offering 'death by Powerpoint', where large numbers of delegates are invited to sit and stare at a Powerpoint screen for an hour, followed by a few questions at the end, IVC and VetSurgeon.org invited a smaller, more intimate group to come and discuss a subject on Zoom, a recording of which was then made available for everyone else to watch later.
In the case of VetSurgeon.org, the first such meeting was 'Let's Talk About Small Animal Surgery' with Alasdair Hotston-Moore: https://www.youtube.com/watch?v=p1rD3zfcUZE
Meanwhile, IVC has based its recent CPD sessions about equine emergencies on a very similar model. During the event, short case studies were presented in a format which allowed for discussion all the way through.
IVC Evidensia Equine Clinical Board Vice Chair, Mark Tabachnik said: "We decided on a reflective, case-based approach rather than the usual monologue, where so much information is thrown at you, you’re lucky to catch a couple of snippets. I wanted something that was a little more relaxed and more collaborative, like a group of colleagues chatting about the cases from their night on call over a drink or two at the pub.”
It's a format which seems to be proving popular. Chessie Greenham of Fyrnwy Vets in Shropshire said: "Interesting cases that reflected on call life, worked through in an approachable style that is easily applied to real life scenarios."
Global names in gastroenterology will be sharing the latest knowledge to help veterinary surgeons and nurses support the work of the BHS and Nottingham University’s REACT to colic campaign, which is designed to help vets and horse owners work together for colic patients.
On Friday 13th September there'll be a two-hour session chaired by Harry Carslake, a diplomate of the American College of Veterinary internal medicine (ACVIM). The session will involve five experts speaking about aspects of colic, followed by discussion and the opportunity for questions from delegates.
Natasha Jocelyn, Internal Medicine Specialist, Sussex Equine Hospital, will speak about managing the acute colic in the field: what to do when flunixin doesn’t work.
Prof. Dr. Gunther Van Loon European Veterinary Specialist in Equine Internal Medicine, Ghent University, Belgium, will discuss managing acute colic in the equine hospital.
Dr Nathan Slovis member of the American College of Internal Veterinary Medicine, Director of the McGee Medicine Department and a partner at Haygard Equine Medical Institute in Lexington, Ky will explain colic guidelines – can ‘algorithms’ help?
Prof. Dr Lutz Goehring European Veterinary Specialist in Equine Internal Medicine, Ludwig-Maximilians University Munich, will explore the question ‘is there an evidence-based approach to managing enteritis?’
David Rendle European Veterinary Specialist in Equine Internal Medicine, Rainbow Equine Hospital, North Yorkshire, will look at parasitic disease as a cause of colic and methods of management.
All BEVA Congress delegates get a certificate of attendance worth seven hours of CPD.
If you're struggling for time or torn between several lectures you can use the BEVA Congress Encore Room to play back missed lectures at your convenience. BEVA Congress is also providing day crèche for children between the ages of 0-8 years. Find out more here.
Anyone who registers for Congress before 8 May 2019 will receive significantly reduced booking fees, and BEVA members save up to £379 on their Congress passes.
Currently used by more than 200 practices and 50 universities around the world, the Equinosis Q is a diagnostic tool that can further aid the subjective lameness evaluation on all types of horses and ponies examined in the field or in hospital settings.
Christina Frigast, MRCVS, Eickemeyer Product Development Manager said: "The inertial sensors sample 20x faster than the human eye making the Equinosis Q a valuable tool to the veterinarian in the evaluation of subtle and multiple limb lameness.
"It does not interfere with the routine lameness examination as trot up on straight line, lunging and ridden evaluations can be performed on both hard and soft surfaces.
"Data is wirelessly streamed to a tablet PC and compiled into a reader-friendly report displaying the timing and severity of lameness. The effectiveness of diagnostic blocks can also be assessed with the Equinosis Q, providing the veterinarian with a percentage of improvement. In addition, comparison reports can be used to monitor rehabilitation progress."
Contact Eickemeyer to book a free demo, or for further information, visit: https://www.eickemeyer.co.uk/Diagnostics-and-Education/Anatomy-Models/Lameness-Locator-vet.html?listtype=search&searchparam=lameness
watch?v=MS6UXQSq6q0
A new study, published in the Equine Veterinary Journal (EVJ)1 has concluded that whilst horse owners are increasingly looking to vets for worm control advice and use faecal worm egg counts more frequently, they remain largely unaware of the threat of resistance to dewormers and the importance of appropriate 'targeted' dosing.
The authors of the study say that although the findings are encouraging, they indicate that further effort is needed to help owners fully understand the issue of dewormer resistance, in order to help preserve the efficacy of dewormers currently available and protect the health and welfare of their horses.
According to the British Equine Veterinary Association (BEVA), resistance of equine gastrointestinal worms to the currently available dewormers is a serious problem. The association says small redworm are the greatest concern, given their very high prevalence, potential to cause life-threatening disease and high levels of resistance. Of the three classes of anthelmintic available for their control, there is now widespread resistance to benzimidazoles (e.g. fenbendazole) and tetrahydropyrimidines (e.g. pyrantel) and reduced effectiveness of macrocyclic lactones (ivermectin and moxidectin). With no new classes of dewormer on the horizon, it's essential that efficacy of existing effective products is preserved.
The study was conducted by a UK team, led by Claire Stratford, Horse Trust Clinical Scholar in Equine Medicine at the Royal (Dick) School of Veterinary Studies, and at Moredun Research Institute. The collaborators were also supported by funding from the Elise Pilkington Trust and Horserace Betting Levy Board.
The study examined equine helminth control practices in Scotland, and was based on responses from 193 questionnaires detailing the parasite control programmes of 993 horses and ponies. The results demonstrated a lack of awareness of the significance of dewormer resistance, with 86% of respondents stating that they were unaware of the presence of resistance on their yard. The majority were relatively unconcerned about dewormer resistance, assigning a score of only 6/10 (with 10 representing highest level of concern) when asked to grade how important they perceived it to be.
On a more positive note, many respondents stated that they involved their vet in planning control strategies. Faecal worm egg count (FWEC) analysis had been performed on 62% of yards and annual treatment frequency had been reduced accordingly. The macrocyclic lactones or related combination products were the most commonly administered products; however, owners did have misconceptions regarding the specific worms they should be targeting.
Although treatments licensed for use against encysted small redworm larvae were administered by 80% of respondents, only 57% perceived that they treated for this parasite stage. Similarly, only 78% of respondents believed they were treating for tapeworm when, in fact, 90% reported using a product licensed for tapeworm treatment.
While responses indicated increased implementation of strategic (44% respondents) or targeted control (40% respondents), variations in the apparent influence of the targeted approach on treatment practices suggested some confusion over this term. Claire Stratford said: "Targeted dosing involves using regular FWEC analysis to identify an individual's egg shedding level. This is currently considered best practice, when used in conjunction with annual dosing against encysted small redworm and tapeworm. The survey indicates a need for continued knowledge transfer, together with a consistent definition of 'targeted' treatment."
Professor Celia Marr, Editor of Equine Veterinary Journal said: "It's very encouraging to see that vet advice is being increasingly sought and it seems logical that the use of FWECs is rising accordingly. But, it is equally important that the information gained from the FWECs is used wisely. Resistance to dewormers is a major health concern that is with us right now and horse owners need to be made more aware of it."
Supplies of the vaccine, which is indicated for the active immunisation for horses against equine arteritis, ran low at the end of last year when Zoetis' existing stock was due to expire without any new stock in place.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
CEVA Animal Health has confirmed its sponsorship of Stephanie Dakin, an equine veterinary PhD student at the Royal Veterinary College in London.
The four-year sponsorship, due to commence October 2008, is being run through the BBSRC Industrial CASE studentship scheme, which involves partnerships between UK-based industrial companies and eligible UK universities or research institutes, to support collaborative postgraduate research. It is the first time that CEVA, the company that recently introduced Tildren®, a treatment for equine bone disease, has undertaken such an initiative in the UK.
Stephanie is conducting her PhD on the pathogenesis and treatment of equine tendonitis. She is currently working with Professor Roger Smith, Professor of Equine Orthopaedics and Dr Jay Dudhia at the RVC, on a study to determine the efficacy of stem cells in the treatment of superficial digital flexor tendonitis in the horse.
Stephanie commented: "I am very keen to direct research in this field in order to better elucidate the mechanisms involved in tendon injury and identify therapeutic targets, such that we can improve our management and hopefully advance our ability to treat and prevent disease, thus improving the health and welfare of equine patients."
She added: "Having the opportunity to undertake this vital research, supported by the BBSRC and the industrial contribution from CEVA, is a real privilege and I hope that the findings from this study will feedback to have a direct, positive impact on clinical cases of tendonitis, in the equine and possibly the human fields."
Dechra Veterinary Products has launched TAF Spray (thiamphenicol), a next generation antibiotic wound spray for superficial wound infections in horses, cattle, goats, sheep and pigs.
Dechra says TAF Spray can also be used to treat infections of the claw and hoof in cattle, goats and sheep such as foot rot, interdigital dermatitis and digital dermatitis.
TAF Spray is the only licensed wound spray for horses and has a zero day meat withdrawal period for horses, cattle, goats, sheep, and 14 days for pigs.
Dechra is also highlighting the fact that TAF Spray is the only golden yellow coloured product of its kind on the market, allowing treatment areas to be distinguished clearly.
Brand Manager Emma Jennings said: “Dechra has developed TAF Spray in direct response to the research we conducted among farmers".
The research1 showed that 51% of the veterinary surgeons had used an antibiotic spray for the treatment of digital dermatitis – an infection that 92% of farmers had experienced in their livestock in the past 12 months.
Emma added: "Thiamphenicol is a highly effective antibiotic. With the brightly coloured spray format making it distinguishable from other treatments and a can that is able to be used in upright and inverted positions, we are sure that TAF Spray will become a popular product among veterinary professionals.”
TAF Spray comes in a 150ml can with a 360-degree nozzle which allows wounds to be targeted at any angle.
For further information about Dechra’s antibiotic portfolio, visit www.dechra.co.uk
Boehringer Ingelheim Vetmedica, manufacturer of the equine pergolide Prascend, has joined forces with the British Horse Society, Redwings Horse Sanctuary and World Horse Welfare to launch the 'Talk About Cushing's (TAC)' campaign.
The initiative, which will take place throughout September and October 2011, is aimed at raising awareness of Cushing's Disease and its clinical signs, perhaps the most familiar of which is hirsutism (abnormal hair growth, or delayed shedding). Horse owners can download a £15 money-off voucher from http://www.talkaboutcushings.co.uk/ throughout the TAC initiative, which can be redeemed through their veterinary practice against blood test costs.
Boehringer says Equine Cushing's Disease, also known as Pituitary Pars Intermedia Dysfunction (PPID), is the most common endocrine disorder in older horses and ponies1 ,and that some estimates suggest over 15% of horses and ponies over 15 years of age are affected2.
Unfortunately, the initial stages of Cushing's Disease are often difficult to detect, delaying the maximum benefit of early diagnosis and intervention. Blood testing is increasingly used to detect the disease and confirm diagnosis, however many horses with clinical signs, including recurrent laminitis, still go undiagnosed.
Craig Beck, vet and equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "More than 80% of horses suffering from laminitis may have an underlying endocrine disorder, such as Cushing's Disease3.
"The TAC campaign will raise awareness of Cushing's Disease amongst both veterinary professionals and owners. It should make it easier for vets to go ahead with endocrine testing in horses and ponies with recurrent laminitis, diagnosing and treating earlier in the course of the disease."
Lee Hackett, head of welfare at the BHS, added: "Cushing's Disease is relatively common in horses yet in our experience it frequently goes undiagnosed and untreated. This is why we are fully behind the 'Talk About Cushing's' campaign - anything that raises awareness and understanding of this disease has to be of benefit to equine welfare."
Redwings' head of veterinary services Nicky Jarvis said: "At Redwings we have many horses over the age of 15, all living very happy and healthy lives. 'Old age' is not in itself a disease so when a geriatric horse loses condition or appears unwell there is always an underlying cause. If a horse continually succumbs to laminitis or loses weight, Cushing's Disease could be one explanation. However, with early diagnosis, good management and the correct treatment a horse with Cushing's can live comfortably for many years."
"Early diagnosis of Cushing's Disease can be of great benefit, other conditions such as laminitis are often associated with it and it is important that clinical signs are recognised and treated appropriately. World Horse Welfare supports the 'Talk About Cushing's' campaign as it will help people to recognise the signs and take the right action to prevent horses from suffering," concludes Tony Tyler, deputy chief executive, World Horse Welfare.
Backed by an advertising and PR campaign in the equine consumer media, Boehringer Ingelheim Vetmedica has produced a marketing pack for veterinary practices to use in the run up to, and during TAC. This includes leaflets, invoice stickers, a veterinary practice toolkit featuring an owner evening presentation, editorial copy for newsletters and websites and images to support the campaign.
For further information on TAC or Prascend, the first licensed product for the treatment of Cushing's Disease, please visit http://www.talkaboutcushings.co.uk/, contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
References
1. Donaldson et al. “Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis”. JAVMA, Vol 224, No. 7, April 1, 20042. McGowan. “Diagnostic and Management Protocols for Equine Cushings Syndrome” In Practice, November/December 20033. McGowan. “Epidemiology and Clinical Perspectives of Endocrinopathic Laminitis”, BEVA Congress 2009
BCF has announced the launch of the wireless Cuattro Slate 4 equine DR system.
BCF says the new system is available with an Automatic Exposure Detection (AED) panel, which means the plate automatically recognises the radiation from the generator, with no need for a sync cable.
Gavin Mitchell from BCF said: "This system now makes the connection from any generator to the plate and from plate to tablet now wireless. This is the new revolution for equine DR. Our rugged tablet design makes it easy to show your client your images. All you need to carry with you is the plate, tablet and generator. So much lighter to transport than previous DR systems and now also easier to move around the horse."
Sarah O'Grady from BCF added: "The powerful Cuattro software is so intuitive to use, allowing you to easily customise how your image looks. A simple three step process to take an image and just one button press to back-up images to PACS or the Cloud, makes the Slate so easy to use. If you are considering upgrading to DR or replacing your old DR system, then make sure you try out the new Slate 4."
For more information, visit www.bcftechnology.com or ask your local Account Manager for a free trial.
Co-edited by Paddy Dixon and Vicki Nicholls, the collection comprises ten studies on physiology, disease, diagnosis and treatment techniques in equine dentistry. The editors say it gives veterinary surgeons free access to some of the most important current research in the UK.
The studies include:
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "Care of the horse’s teeth is fundamental to good health. To this end a strong working knowledge of equine dentistry should be seen as an essential cornerstone for every equine practitioner. This diverse collection has the convenience of being easily accessible, online and in one place to help keep vets fully abreast of the excellent research currently being conducted in the UK."
Vicki Nicholls, incoming president of BEVA, continued: "Advances in equine dentistry continue to gather pace and it has been a pleasure and privilege to work with Paddy Dixon collating the most current dental research that will be relevant to all equine practitioners with any level of expertise."
The equine dentistry collection is available free online at: http://bit.ly/2bBDuMW.
Veterinary practices are being urged to raise awareness of summer skin conditions, such as sweet itch, following research carried out by Elanco Companion Animal Health, distributor of Cavalesse, which revealed that vets only tend to be consulted after horse owners have tried to manage the condition themselves (73%), or if the clinical signs have become severe (67%), potentially leading to major welfare implications.
According to the research, this is despite the fact that over half (55%) of owners of a horse with sweet itch showed concern that their horse will suffer, and nearly half being stressed about the way the condition will affect it (47%). While many horse owners are fairly knowledgeable about the causes of sweet itch and its clinical signs, over a quarter of respondents (26%) did not start managing the condition before the midge season in the spring, which may make managing the condition more frustrating. Nearly a third (31%) stated that they had to curtail their activities with their horse due to welfare, aesthetic and behavioural issues, such as head shaking, rubbing, unpredictability and aggression.
Ed Whittle, technical consultant at Elanco Companion Animal Health said: "86% of those questioned considered sweet itch to be a very serious welfare issue if left untreated, with the worst aspects of the condition being the suffering and distress caused by the constant irritation which affects the quality of life of the horse. Over half (55%) felt that sweet itch had adversely affected the behaviour of their horse, making them difficult to handle or ride. Veterinary practices should be proactively talking to their clients about summer skin conditions such as sweet itch to help alleviate the suffering and distress caused by this frustrating disease."
Elanco says it will be joining forces with the British Horse Society (BHS), The Blue Cross, The Horse Trust, Redwings Horse Sanctuary and World Horse Welfare (WHW) to raise awareness of summer skin conditions, such as sweet itch, during Sweet Itch Awareness Month (SIAM) in March. The campaign will highlight the preventative measures that should be carried out to help alleviate sweet itch and the importance of management of the condition before the start of the midge season in the spring.
Lee Hackett, head of welfare at the BHS, said: "The results of this survey show just how important raising awareness of sweet itch is. All of us, whether we are welfare organisations or vets, need to play our part in educating owners about sweet itch in the hope that they will seek expert advice at an earlier stage and reduce the number of horses that suffer as a result of this condition."
Kerry Taylor, education officer at The Blue Cross, said: "The Blue Cross is pleased to be supporting the sweet itch campaign to raise awareness of the physical and mental impact this condition has on horses. During our May 2011 National Equine Health Survey, skin problems came out the top syndrome affecting horses, and we continue to see many horses coming into our care suffering from sweet itch. Prevention and early treatment is key to managing the potentially debilitating condition."
For further information on sweet itch, Sweet Itch Awareness Month or Cavalesse, please visit http://www.fidavet.com/, or contact Elanco Companion Animal Health, Lilly House, Priestley Road, Basingstoke, RG24 9NL, 01256 353131.
Sweet itch - effect on horse and owner. Mo Gannon & Associates. Web survey in November 2011. 351 responses - owners who have owned horses with sweet itch in the last two years.
Pfizer Animal Health has launched a dedicated Equine Business Unit to provide a higher level of service and a comprehensive range of products to equine vets across the UK.
Created following the merger with Fort Dodge, the Pfizer Equine Business Unit is headed by Ben Lacey MA Vet MB MRCVS, who has previously held both technical and sales roles at Pfizer. Ben and his team have a brief to offer a breadth of product, support and flexibility not previously available to equine vets.
The product range offered by the Pfizer Equine Business Unit includes the Equest range of parasiticides; the Duvaxyn vaccines for Equine Herpes Virus, West Nile Virus and Rotavirus and products such as Equimidine and Torbugesic. Also offered are existing Pfizer brands such as the Equip vaccine range, the antibiotic Excenel Sterile Powder, the NSAID Rimadyl for Horses and Depo-MedroneV.
Five experienced account managers with a strong track record in the equine sector have been appointed by Pfizer to build relationships with equine vet practices on a regional basis. They are:
South East England Mark BakerWest Midlands, Cheshire, Wales Laurie MayEast Anglia, East Midlands Penny McCannSouth West, South Wales Anna CunninghamThe North, Scotland Alexandra Cox
Ben Lacey said: "Building our new team and combining the highly regarded products offered previously by both Fort Dodge and Pfizer has proved a stimulating process. We've also worked closely with many of our existing practice customers to look at how we can develop the service we provide to them.
"We're now able to offer a product range which I believe is unrivalled in the market and a highly committed team of equine professionals, who share a vision and passion for equine health. We're looking forward to building our business with both existing and new customers in the months ahead."
The webinars each last between three and five minutes and are part of the 2016 ‘Talk About Laminitis’ disease awareness initiative to help detect, manage and monitor PPID.
The webinars can be viewed on the Boehringer Academy website – www.boehringer-academy.co.uk - and podcast versions are also available enabling veterinary professionals to listen to them ‘on the go’.
The first series includes:
The second webinar series covers:
For further information on the webinars or podcasts visit www.boehringer-academy.co.uk or contact your local Boehringer Ingelheim territory manager.
Centaur has launched a new service on the MyCentaur website which allows for 24-hour ordering from any broadband enabled computer.
A secure practice shopping list with controlled staff access to ordering and management information enables practices to safely control any buying.
According to the company, a key feature of the website is that any orders placed on line by 9pm will be delivered the following day, which gives practices even greater flexibility on ordering times over any existing vet wholesaling ordering service. As well as greater convenience, a financial benefit in using this method of ordering is that all on-line orders attract an additional two per cent discount.
The company says that so far, it has had no cases of flu reported in horses vaccinated with Equip F or Equip FT in the UK. However, it cautions that in the present flu outbreak it is not clear if any of the current influenza vaccines will provide complete clinical protection against the mutated strain.
In addition, Zoetis highlights that:
Equip F and Equip FT are both indicated for reduction in clinical signs caused by Equine Influenza, including Florida Clade 1 strains.
Cross protection has been demonstrated by virulent challenge for representative strains of Florida Clade 1 (Paillot et al 20081, Bryant et al 20102) and Clade 2 (Paillot et al 20153).
Vaccination with Equip F stimulated a flu specific cell-mediated immune response to a Clade 1 strain which was detectable for up to one year after the third vaccination in primary course (Paillot et al 20153).
Zoetis says it is confident that the Equip range continues to be effective against its licensed indications.
If you have further questions about the vaccines, ring 0845 300 8034 and choose option 1 to speak to Zoetis' technical team.
BEVA Congress 2021 will now take place from September 4th-7th 2021.
The decision to cancel Congress 2020 was taken by BEVA Council and the Congress programme committee because of the unpredictable circumstances of the coronavirus pandemic.
Tim Mair, President of BEVA said: “The overriding factor in our decision-making process was to protect everyone attending Congress. We are chartering unknown territory at the moment and the additional planning requirements needed to run a large event like BEVA Congress with social distancing measures in place will take time.
“We intend for September 2021 to mark an exciting, fresh start for the profession following the harrowing experiences of 2020. It should be safe for our international speakers and delegates to attend by then, getting us all back on track with networking and world-class CPD to inspire us for the new post Covid-19 world.”
Tickets for BEVA Congress 2021 will be available later this year, more information from: www.bevacongress.org.
Preliminary results, which recorded a decline in the quantities of antimicrobials prescribed from 2014 to 2018, were published in 2022.
A further audit has now been undertaken in all 22 of the company's first opinion practices to investigate the age, breed and estimated weight of each horse, the clinical indication for antibiotic use, the drugs prescribed, their dose rates, the route of administration and whether culture and sensitivity were used to guide antimicrobial selection.
Data collection was completed in August 2022.
This secondary audit was conducted using a ‘point prevalence’ survey, in which each CVS Equine first opinion Quality Improvement Lead gathered information about all systemic antibiotics prescribed by each of their practices on one day a month for 12 consecutive months.
The project yielded information on 331 cases where systemic antimicrobials were prescribed.
Complete data about the first line-drug selection were available for 261 prescriptions.
The commonest prescribed antimicrobial was sulfadiazine/trimethoprim (41%), followed by oxytetracycline (23%), procaine penicillin (16%), doxycycline (13%), gentamicin (4%), metronidazole (1%), ceftiofur (1%) and enrofloxacin (1%).
Highest priority critically important antimicrobials (ceftiofur and enrofloxacin) were only prescribed in four horses (clinical indications for these included possible sepsis, skin infection, lower respiratory tract infection and a wound complication – in none of these cases was the first-line drug selection based on the results of culture and sensitivity.
Overall, the clinical indications for antimicrobial use were recorded in 246 cases; the commonest indications were cellulitis/lymphangitis (27%), uncomplicated wounds (19%), surgical prophylaxis (15%), respiratory infections (11%) and skin infections (8%).
Hattie Lawrence, Director of CVS Equine, said: “Though the impact of this work is yet to be documented, there is anecdotal evidence that it has raised awareness amongst our veterinarians of the importance of antimicrobial stewardship.
"Taken together, the results of both pieces of work will be used to help develop and inform clinical audits and clinical guidelines of antimicrobial use in horses.”
Thus far, the hospital has relied on conventional radiographs or referred for MRI for the bulk of its distal limb imaging.
The new Hallmarq standing CT scanner provides information that surpasses the capabilities of radiography, while also reducing radiation exposure to the patients and staff.
The scanning process is also considerably quicker, enabling prompt diagnosis and treatment planning.
Tom McParland, Valley Equine Hospital’s surgeon said: "We are confident that this diagnostic modality will significantly enhance our ability to identify not just thoroughbred fetlock pathology earlier but improve our diagnostic abilities of the distal limb for all our equine patients, racing and leisure alike.”
Valley Equine Hospital says it chose the Hallmarq standing CT scanner due to its ability to scan using just standing sedation which ensures a safer and more efficient experience for the horses compared to general anaesthesia.
www.valleyequinehospital.co.ukinfo.hallmarq.net/focus-on-the-foot
Squamous cell carcinoma affects horses’ genitalia, eyes, or skin around the eyes. The tumours typically have a guarded to poor prognosis, and the therapeutic approaches available have variable success rates. Euthanasia on welfare grounds is necessary in a significant number of cases.
Before this new research was published, pathologists and researchers Dr Alejandro Suárez-Bonnet and Professor Simon Priestnall, both from the RVC, had already undertaken research which showed that equine squamous cell carcinoma affecting the penis frequently acquires the ability to degrade the extracellular matrix and become much more biologically aggressive2. This is known as ‘epithelial to mesenchymal transition’.
This new study, recently published in Scientific Reports, is the product of a multi-institutional effort, which used both “classical” anatomic histopathology assessment and artificial intelligence to demonstrate a correlation between chronic inflammation, equine papillomavirus infection and progression of equine penile squamous cell carcinoma.
Several additional cancer-related signalling molecules, which are important in researchers’ understanding of human penile cancer, were also studied and the results obtained will lead to a much better understanding and treatment of the cancer.
Simon Priestnall, Professor of Veterinary Anatomic Pathology at the Royal Veterinary College, said: “Equine squamous cell carcinoma is the second most common type of cancer in horses, with a variable prognosis, so we are delighted to have made this breakthrough that provides a greater understanding and can lead to more effective treatments for horses and their owners.
"The RVC has always recognised the value of collaboration, and Alejandro and I enjoyed working alongside the teams at KCL, the University of Edinburgh and UCL. This project shows what can be achieved when different organisations work together with a common aim and we hope the similarities between the tumour in horses and people can offer a true One Health benefit."
Dr Alejandro Suárez-Bonnet, Lecturer in Comparative Pathology at the Royal Veterinary College, said: "I am so pleased with the results of this study, which will hopefully pave the way for improved prognosis of horses diagnosed with equine squamous cell carcinoma.
"Our work is not over, however. Thanks to the help of a grant from the Horse Race Betting Levy, Simon and I are leading a Master’s degree project investigating equine penile, ocular and vulvar squamous cell carcinomas from a broader perspective.
"Our hope is to identify if variability exists between equine papillomavirus infectious status, morphological and microscopic difference, and cancer progression, with the aim of identifying potential therapeutic targets as well as diagnostic markers with prognostic implications for maximum benefit to the British equine population.”